Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Alkermes plc
  6. News
  7. Summary
    ALKS   IE00B56GVS15

ALKERMES PLC

(ALKS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Alkermes : Presents Nemvaleukin Alfa Data at American Society of Clinical Oncology Annual Meeting

06/04/2021 | 03:34pm EDT


ę MT Newswires 2021
All news about ALKERMES PLC
08:26aALKERMES : Secures FDA Fast Track Designation for Melanoma Treatment
MT
07:01aALKERMES : Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Trea..
PR
07/29ALKERMES : Reports Second Quarter 2021 Financial Results
AQ
07/29ALKERMES : Mizuho Securities Adjusts Alkermes' Price Target to $33 From $29, Mai..
MT
07/29ALKERMES : SVB Leerink Adjusts Alkermes' Price Target to $25 From $23, Keeps Mar..
MT
07/28ALKERMES : Reports Earnings, Revenue Increase for Q2, Raises Full-Year Guidance
MT
07/28ALKERMES : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
07/28ALKERMES : Q2 2021 Earnings slides Final 7 27 21 607pm.pdf
PU
07/28ALKERMES : Q2 Earnings Snapshot
AQ
07/28ALKERMES : Reports Second Quarter 2021 Financial Results (Form 8-K)
PU
More news
Financials (USD)
Sales 2021 1 171 M - -
Net income 2021 -79,9 M - -
Net cash 2021 365 M - -
P/E ratio 2021 -54,3x
Yield 2021 -
Capitalization 4 174 M 4 174 M -
EV / Sales 2021 3,25x
EV / Sales 2022 2,91x
Nbr of Employees 2 245
Free-Float 96,7%
Chart ALKERMES PLC
Duration : Period :
Alkermes plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALKERMES PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Last Close Price 25,87 $
Average target price 25,00 $
Spread / Average Target -3,36%
EPS Revisions
Managers and Directors
Richard F. Pops Chairman & Chief Executive Officer
Iain Michael Brown Senior VP, Chief Financial & Accounting Officer
Craig C. Hopkinson Chief Medical Officer & EVP-Research & Development
Thomas Harvey Chief Information Officer & Senior VP-IT
Sondra Smyrnios Senior Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
ALKERMES PLC29.67%4 174
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
IQVIA HOLDINGS INC.38.25%47 462
CELLTRION, INC.-26.60%30 059
SEAGEN INC.-12.42%27 907